Table 1. Summary of retrospective reviews and case series evaluating oncologic efficacy of partial cystectomy.
| Retrospective study/case series | No. patients | Study design | Oncologic outcomes | Mean follow-up (months) |
|---|---|---|---|---|
| Holzbeierlein et al. (9) | 58 PC | Inclusion criteria: primary bladder tumor of non-urachal origin | 5-year advanced RFS: 67%; 5-year OS: 69% | 33.4 |
| Kassouf et al. (6) | 37 PC | Inclusion criteria: (I) solitary tumor; (II) absence of CIS; (III) 2 cm surgical margin; (IV) not requiring ureteral reimplant | 5-year RFS: 39%; 5-year DSS: 87%; 5-year OS: 67% | 72.6 |
| Smaldone et al. (10) | 25 PC | Inclusion criteria: (I) solitary, urothelial tumor; (II) absence of CIS; (III) negative surgical margin. Protocol: (I) pre-operative radiation (25 Gy); (II) 6 weeks of BCG post-operatively | 5-year RFS: 62%; 5-year DSS: 84%; 5-year OS: 70% | 45.3 |
| Golombos et al. (31) | 29 PC | Included urothelial and variant histology (adenocarcinoma, squamous, neuroendocrine, micropapillary, myxoid) | 5-year RFS: 68%; 5-year OS: 79% |
37.0 |
| Koga et al. (32) | 46 PC | Inclusion criteria: (I) intravesically circumscribed tumor; (II) bladder neck and trigone uninvolved; (III) no residual tumor or only NMIBC at restaging after chemoradiation. Protocol: (I) pre-operative radiation (40 Gy); (II) pre-operative cisplatin (2 cycles) |
5-year MFS: 100%; 5-year DSS: 100% |
45 (median) |
| Knoedler et al. (33) | 167 RC; 86 PC | 1:2 matched case-control study comparing PC to RC | RC: 10-year MFS: 66%; 10-year DSS: 63%; 10-year OSS: 36%. PC: 10-year MFS: 61%; 10-year DSS: 58%; 10-year OS: 36% |
74.4 |
| Capitanio et al. (34) | 5670 RC; 1573 PC | Matched case-control study from SEER database comparing PC to RC in patients with T1-4, N0-2, M0 disease | RC: 5-year DSS: 65.8%; 5-year OS: 50.2%. PC: 5-year DSS: 76.4%; 5-year OS: 57.2% |
77.0; 64.0 |
| Herr et al. (35) | 17 RC; 15 PC | (I) Patients underwent 4 cycles of neoadjuvant MVAC; (II) Case-control comparing RC to PC for those patients who were rendered T0 after chemotherapy | RC: 10-year MFS: 65%. PC: 10-year MFS: 73% | 120 (median) |
| Sternberg et al. (36) | 39 RC; 13 PC | (I) Patients underwent 3 cycles of neoadjuvant MVAC; (II) Inclusion criteria for PC: complete or partial response to MVAC, solitary lesions, no CIS, good capacity bladder; (III) RC selected based on lack of chemotherapy response | RC: 5-year OS: 46%. PC: 5-year OS: 69% |
45 (median); 88 (median) |
PC, partial cystectomy; RC, radical cystectomy; RFS, recurrence-free survival; MFS, metastasis-free survival; DSS, disease-specific survival; OS, overall survival; NMIBC, non-muscle invasive bladder cancer; MVAC, methotrexate, vincristine, doxorubicin, cisplatin.